Jefferies Cuts Target to $60 on Watson Pharmaceuticals

Jefferies reiterates its Hold rating on Watson Pharmaceuticals WPI and lowers its price target by $10 to $60 on a largely disappointing outlook presented at the company's analyst day. Jefferies says, "At its analyst day, WPI provided a '12 EPS outlook that largely disappointed, but more importantly for us, '13 guidance of ~10% growth (a year of tough comps, given gx Lipitor loss) was reassuring. We now raise '13 EPS to $5.98 (vs. our prior $4.22), but note that we're only there due to formal guidance. WPI seems to have the pieces to grow in 2013, but since it is still not 100% obvious to us how WPI gets there, we maintain our Hold." WPI closed at $55.89 a share on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!